Background. One of the essential medical tasks is an efficient choice of dosage forms according to main points of biopharmaceutical concepts. An advantageous object for such development is a dry as-pen bark extract (“Ekorsin”), created by joint collaboration of Pharmaceutical technology department, ASMU, RIPRM named E.D. Goldberg and CJSC “Altaivitaminy”. Its pilled dosage form showed high antiulcer activity at preclinical stage which was confirmed at clinical stage. Methods. For a comparative study of the pharmacological activity of the tablets “Ekorsin” and newly developed dosage form - capsules “Ekorsin forte”- conventional models of neurogenic and indometacin ulcerogenesis were used in two animal species. Results. In the context of the model of neurogenic ulcer formation in mice revealed preferential antiul-cer efficacy of capsule with a mixture of dry aspen bark extract. In the context of indometacin defect of gastric mucosa in mice revealed prominent antiulcer efficacy of a capsule mixture which were more active than pills. conclusions. Benchmark assessment of antiulcer activity in two models of experimental ulcerogenesis in mice and rats suggests surpassing activity of the capsules “Ekorsin forte” to pills “Ekorsin”. Activity varied depending on genesis of ulcerous destruction.